| Product Unit Size | Cost | Quantity | Stock |
|---|
Afuresertib is an inhibitor of Akt, a serine/threonine kinase. In addition to showing efficacy in clinical trials as a monotherapy against hematological malignancies, afuresertib has been effective against multiple myeloma. When used in combination with pomalidomide plus dexamethasone, afuresertib exhibited antitumor activity in multiple myeloma cells. It has also shown efficacy in patients with malignant pleural mesothelioma.
| Cas No. | 1047644-62-1 |
|---|---|
| Purity | ≥98% |
| Formula | C18H17Cl2FN4OS |
| Formula Wt. | 427.32 |
| IUPAC Name | N-[(2S)-1-Amino-3-(3-fluorophenyl)-2-propanyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide |
| Synonym | GSK-2110183C, GSK-2110183 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet |
|---|
Kinoshita S., Ri M., et al. Potent antitumor effect of combination therapy with sub-optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma. Oncol Lett. 15(6):9450-56 (2018). PMID: 29927335.
Yamaji M., Ota A., et al. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 6(11):2646-59 (2017). PMID: 28960945.
